PURPOSE: Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. PATIENTS AND METHODS: A total of 162 patients with intracranial glioblastoma multiforme or gliosarcomas who had undergone surgery andradiotherapy participated in this multicenter, double-blind, placebo-controlled, parallel group study conducted at 20 institutions. Seventy-nine patients (57 male, 22 female, median age 58 years) were randomized to receive placebo (PB), and 83 patients (51 male, 32 female, median age 57 years) were randomized to receive MT, 10 mg orally twice daily, until tumor progression. RESULTS: This intention-to-treat efficacy analysis showed no statistically significant difference between MT and PB groups with respect to survival (P = 0.38, log rank test). The median survival time from protocol initiation was 37.9 weeks for the PB group and 42.9 weeks for the MT group, with a hazard ratio of 1.16 (95% CI 0.83 to 1.60). There were no statistically significant differences in quality of life between the PB and MT groups, as assessed by the FACT-BR questionnaire. Musculoskeletal toxicities led to dose modification or withdrawal in 20% of MT-treated and 1.2% of PB-treated patients. CONCLUSION:MT does not improve survival in patients with glioblastoma or gliosarcoma following surgery and radiotherapy. Therefore, single-agent MT appears unwarranted; however, MT in combination with cytotoxic chemotherapy may be warranted, as suggested by observations in our study and other studies.
RCT Entities:
PURPOSE: Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. PATIENTS AND METHODS: A total of 162 patients with intracranial glioblastoma multiforme or gliosarcomas who had undergone surgery and radiotherapy participated in this multicenter, double-blind, placebo-controlled, parallel group study conducted at 20 institutions. Seventy-nine patients (57 male, 22 female, median age 58 years) were randomized to receive placebo (PB), and 83 patients (51 male, 32 female, median age 57 years) were randomized to receive MT, 10 mg orally twice daily, until tumor progression. RESULTS: This intention-to-treat efficacy analysis showed no statistically significant difference between MT and PB groups with respect to survival (P = 0.38, log rank test). The median survival time from protocol initiation was 37.9 weeks for the PB group and 42.9 weeks for the MT group, with a hazard ratio of 1.16 (95% CI 0.83 to 1.60). There were no statistically significant differences in quality of life between the PB and MT groups, as assessed by the FACT-BR questionnaire. Musculoskeletal toxicities led to dose modification or withdrawal in 20% of MT-treated and 1.2% of PB-treated patients. CONCLUSION:MT does not improve survival in patients with glioblastoma or gliosarcoma following surgery and radiotherapy. Therefore, single-agent MT appears unwarranted; however, MT in combination with cytotoxic chemotherapy may be warranted, as suggested by observations in our study and other studies.
Authors: V A Levin; J H Uhm; K A Jaeckle; A Choucair; P J Flynn; M D Prados; J M Bruner; S M Chang; A P Kyritsis; M J Gleason; K R Hess Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: J S Rao; M Yamamoto; S Mohaman; Z L Gokaslan; G N Fuller; W G Stetler-Stevenson; V H Rao; L A Liotta; G L Nicolson; R E Sawaya Journal: Clin Exp Metastasis Date: 1996-01 Impact factor: 5.150
Authors: R E Sawaya; M Yamamoto; Z L Gokaslan; S W Wang; S Mohanam; G N Fuller; I E McCutcheon; W G Stetler-Stevenson; G L Nicolson; J S Rao Journal: Clin Exp Metastasis Date: 1996-01 Impact factor: 5.150
Authors: Zev A Binder; Amy Haseley Thorne; Spyridon Bakas; E Paul Wileyto; Michel Bilello; Hamed Akbari; Saima Rathore; Sung Min Ha; Logan Zhang; Cole J Ferguson; Sonika Dahiya; Wenya Linda Bi; David A Reardon; Ahmed Idbaih; Joerg Felsberg; Bettina Hentschel; Michael Weller; Stephen J Bagley; Jennifer J D Morrissette; MacLean P Nasrallah; Jianhui Ma; Ciro Zanca; Andrew M Scott; Laura Orellana; Christos Davatzikos; Frank B Furnari; Donald M O'Rourke Journal: Cancer Cell Date: 2018-07-09 Impact factor: 31.743
Authors: Mohan S Nandhu; Prajna Behera; Vivek Bhaskaran; Sharon L Longo; Lina M Barrera-Arenas; Sadhak Sengupta; Diego J Rodriguez-Gil; E Antonio Chiocca; Mariano S Viapiano Journal: Clin Cancer Res Date: 2017-11-16 Impact factor: 12.531
Authors: David M Peereboom; Dale R Shepard; Manmeet S Ahluwalia; Cathy J Brewer; Neeraj Agarwal; Glen H J Stevens; John H Suh; Steven A Toms; Michael A Vogelbaum; Robert J Weil; Paul Elson; Gene H Barnett Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130